Healthcare Professionals' Views on the Management of Medication Complexities in the Elderly With Mental Health Disorders: A Cross-Sectional Study

Social networks use in the context of Schizophrenia: a review of the literature

Schizophrenia is a persistent mental health condition that, while presenting challenges, underscores the dynamic nature of cognitive functions and encourages a unique perspective on how individuals engage with their surroundings. Social networks, as a means of communication of great importance at the present time, are for this type of people a way of interacting with their environment with a high level of security. The aim is to find out how schizophrenia is dealt with in different social networks and to differentiate between different types of articles dealing with the use of Facebook, X (former Twitter), YouTube, TikTok, Instagram, and Weibo. A total of 45 articles to i) Social networks used, ii) Country of analyzed users, iii) age of the users analyzed, iv) focus of the analyzed manuscript (mental health literacy, stigmatization, detection of patterns associated with schizophrenia, and Harmful substance use). It was observed that 45.45% of the studies analyzed were conducted in the USA population, followed by UK and China (13.64%). The most analyzed social networks were those based on audiovisual communication (60%). Furthermore, the two main foci addressed in these articles were: stigmatization of schizophrenia with 16 articles (35.55%), following by the prediction of schizophrenia-detecting patterns with 15 articles (33.33%) and the use of social networks to stigmatize people with schizophrenia (38%) and only 14 articles (31.11%) were focused on mental health literacy. Likewise, it was found that there is great potential in the use of the analysis of the content generated, as possible predictors of the presence of this disease, which would allow rapid detection and intervention for psychosis and schizophrenia.

unDerstandIng the cauSes of mediCation errOrs and adVerse drug evEnts for patients with mental illness in community caRe (DISCOVER): a qualitative study

Background

It is estimated that 237 million medication errors occur in England each year with a significant number occurring in the community. Our understanding of the causes of preventable medication errors and adverse drug events (ADE) affecting patients with mental illness is limited in this setting. Better understanding of the factors that contribute to errors can support the development of theory-driven improvement interventions.

Methods

Remote qualitative semi-structured interviews with 26 community-based healthcare professionals in England and Wales were undertaken between June-November 2022. Recruitment was undertaken using purposive sampling via professional networks. Interviews were guided by the critical incident technique and analysed using the framework method. Any data that involved speculation was not included in the analysis. Independent analysis was carried out by the research team to extract themes guided by the London Protocol.

Results

A total of 43 medication errors and 12 preventable ADEs were discussed, with two ADEs having an unknown error origin. Prescribing errors were discussed most commonly (n = 24), followed by monitoring errors (n = 8). Six contributory factor themes were identified: the individual (staff); the work environment; the teams/interfaces; the organisation and management; the patient; and the task and technology. The individual (staff) factors were involved in just over 80% of all errors discussed. Participants reported a lack of knowledge regarding psychotropic medication and mental illnesses which accompanied diffusion of responsibility. There were difficulties with team communication, particularly across care interfaces, such as ambiguity/brevity of information being communicated and uncertainty concerning roles which created confusion amongst staff. Unique patient social/behavioural contributory factors were identified such as presenting with challenging behaviour and complex lifestyles, which caused difficulties attending appointments as well as affecting overall clinical management.

Conclusion

These findings highlight that the causes of errors are multifactorial with some unique to this patient group. Key areas to target for improvement include the education/training of healthcare professionals regarding neuropharmacology/mental illnesses and enhancing communication across care interfaces. Future research should explore patient perspectives regarding this topic to help develop a holistic picture. These findings can be used to guide future intervention research to ameliorate medication safety challenges for this patient group.

Clinical pharmacy services in mental health in Europe: a commentary paper of the European Society of Clinical Pharmacy Special Interest Group on Mental Health

A large proportion of the world's disease burden is attributable to mental illnesses. Although effective interventions are available, many patients still have limited access to evidence-based treatments. Aside from access, treatment gaps, including inappropriate medication selection and monitoring, are also routinely recognised. Mental health clinical pharmacists can help address these gaps and enable patients to receive optimised pharmaceutical care, particularly appropriate medication selection and monitoring. The European Society of Clinical Pharmacy (ESCP) Special Interest Group on Mental Health was established to improve standardised service provision in mental health settings across Europe. The Special Interest Group identified significant barriers (predominantly associated with reimbursement and position within the multidisciplinary team) to effective pharmaceutical care amongst those with mental illnesses. This commentary presents recommendations to address these gaps through improved mental health clinical pharmacy service provision.